Key takeaways from the Qserve MedTech Conference 

Last week, the Purdie Pascoe team joined Qserve Group in Amsterdam for its MedTech Conference, with Marcus Torr, Alice Roberston, Chris Webb and Tonika Chester attending from the team. 

Marcus also took to the stage alongside Bianca Lutters to discuss how MedTech companies can use real-world data and turn it into a meaningful regulatory asset. 

From clinical evidence and Post-Market Surveys to AI and MDR 2.0, here are some of the key themes the team took away from the conference.  

From real-world data to meaningful evidence 

One of the clearest messages was that collecting data isn't enough. Real-world data does not become real-world evidence simply because it has been collected. It needs to answer a defined clinical or regulatory question, be relevant to the specific device and population, and be generated through a reliable and defensible process. 

Rather than starting with a particular method, the approach should be to identify the evidence gap, assess the data already available and select a proportionate method capable of answering the question rigorously. 

A proportionate approach to clinical evidence 

Not every device requires the same type or extent of clinical evidence. What matters is having an appropriate, robust and scientifically justified evidence strategy that reflects the device's intended purpose, risk profile and available clinical data. 

PMS, PMCF, risk management and clinical evaluation should also work as one connected lifecycle process, rather than separate activities. Earlier communication between manufacturers, regulators and Notified Bodies can help clarify expectations and potentially avoid delays and unnecessary costs later. 

The role of Post-Market Surveys 

Well-designed Post-Market Surveys can play an important role within this evidence strategy, providing structured real-world insights into device performance, user experience and clinical outcomes. 

However, a survey shouldn't simply be viewed as a PMCF box to tick or an automatic alternative to a clinical investigation. The question should determine the method. 

AI and MDR 2.0 

AI was another major topic. While it can help structure information, identify inconsistencies and analyse large volumes of data, outputs still require independent human review. Transparency around when, where and how AI has been applied will also remain important. 

There was also plenty of discussion around MDR 2.0 and the need for a more predictable and proportionate regulatory system. While upcoming revisions remain uncertain, future reform is unlikely to remove the need for high-quality clinical evidence. 

The bigger picture 

Perhaps the strongest takeaway was the need to move beyond collecting data simply to satisfy an obligation. 

Instead, the opportunity is to generate evidence that is relevant, reliable, traceable and capable of supporting a real decision. 

A huge thank you to Qserve Group for bringing together the MedTech regulatory and clinical community for such an open and collaborative few days. 


Need support with your post-market evidence strategy?
Our team helps MedTech companies generate robust real-world evidence through well-designed Post-Market Surveys.

Marcus Torr

Marcus is Head of Post Market Surveys at Purdie Pascoe, with extensive experience in quantitative research and post-market data collection for the medical device industry. Since taking leadership of the Post Market Survey team in 2019, Marcus has overseen more than 600 surveys across a wide range of medical device types, supporting global manufacturers with PMCF, PMPF and wider real-world data collection. He has extensive knowledge of post-market survey requirements and delivering robust survey solutions to support global regulatory compliance.

https://www.linkedin.com/in/marcus-torr-6b72a378/
Next
Next

Strong clinical evidence is only part of the value story